Butterfly Network Stock Soars 56% on Midjourney Deal: Buy or Sell in 2026?
Butterfly Network shares rose 55.87% to $8.90 on June 18 after AI startup Midjourney said it built a full-body ultrasound scanner using 40 Butterfly Ultrasound-on-Chip modules. The companies’ licensing/co-development deal could bring Butterfly up to $74M in expected payments, and Butterfly reported Q1 revenue of $26.5M (+25%) and gross margin of 68.9%, while maintaining 2026 revenue guidance of $117M–$121M.
How this was made
The 30-second read
Why it matters
A quantified expected payments figure ($74M) tied to a high-visibility AI startup prototype can materially change near-term expectations, but the article stresses unresolved regulatory clearance, commercialization, scaling, and continued losses/negative free cash flow.
Market read
Traders should treat this as a catalyst-driven re-rating with elevated volatility: the deal is news, but the path to revenue realization is uncertain and profitability/valuation concerns are immediate headwinds.
What to watch
Watch for (1) whether analysts revise EPS/revenue estimates after the deal, (2) evidence of regulatory pathway progress, and (3) whether module supply/manufacturing constraints limit commercialization timing.
Background
Butterfly Network is a small-cap medical imaging company positioning its ultrasound modules and AI ecosystem for point-of-care use; the article frames the Midjourney deal as a potential licensing/co-development revenue driver.
Ticker impact
Butterfly Network shares jumped ~56% after Midjourney said it built a full-body ultrasound scanner using 40 Butterfly modules and expects up to $74M payments.
Elevated volatility likely persists; upside depends on follow-through (regulatory clearance, commercialization, scalable module supply) and any subsequent earnings estimate revisions.
The article cites a new partnership/prototype linkage and quantified expected payments, but also highlights unresolved regulatory/commercialization milestones and ongoing losses/FCF burn.
Market effects
Could increase investor attention on AI-enabled point-of-care imaging and ultrasound module licensing models, pressuring peers to justify differentiation and timelines.
Primarily US small-cap medical device sentiment; may spill into broader medtech/diagnostics risk appetite.
High-profile international AI-health collaboration narrative may attract global capital to ultrasound/medical imaging innovation themes.
Counterpoint
The rally may be momentum/speculative: the scanner is still a prototype with major regulatory, adoption, and scaling hurdles, while profitability remains weak and valuation is rich.
Key entities
- companyButterfly Network
US-listed medical imaging company whose shares surged on a Midjourney partnership using Butterfly ultrasound modules.
- companyMidjourney
AI startup whose blog claims it built a whole-body ultrasound scanner using Butterfly modules and plans a San Francisco health facility.
